The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma.
Sani Haider Kizilbash
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Jesse S Voss
No relevant relationships to disclose
Paul A. Decker
No relevant relationships to disclose
Robert B. Jenkins
No relevant relationships to disclose
Nadia N. Laack
No relevant relationships to disclose
Ian F Parney
No relevant relationships to disclose
Joon H. Uhm
No relevant relationships to disclose
Jan C. Buckner
No relevant relationships to disclose